Arth by Emcure is a specialized range of supplements designed to address the unique health and wellness needs of women, enabling them to lead healthier and happier lives across all stages
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
The company remains focused on strengthening its direct retail presence and expanding its reach to more customers across India.
Subscribe To Our Newsletter & Stay Updated
